*December 2019* With the inevitability of resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutant non–small
*December 2019* SEONGNAM, South Korea, Dec. 19, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that
*December 2019* Adding chemotherapy to a targeted agent doubled progression-free survival (PFS) for patients with advanced EGFR-mutant non-small cell lung
*December 2019* Patients with EGFR-mutant (m) non-small-cell lung cancer (NSCLC) and leptomeningeal metastases (LM) respond favorably to high daily doses of
*November 2019* Phase II progression on any TKI with a new 3rd generation TKI, lazertinib. Location: Montefiore/Einstein in NYC. More
*September 2019* by Dr. Mark Kris for Medscape This is Mark Kris from Memorial Sloan Kettering. Just when we thought
*June 2019* by Nichole Tucker for Targeted Oncology Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have
*October 2019* by Caroline Seymour for OncLive Insight into the natural history of EGFR-, ALK-, and ROS1-positive non–small cell lung
*October 2018* by Shalmali Pal Medpage Today and ASCO Chimeric antigen receptor (CAR) T-cell therapy took a victory lap in early
*August 2019* Science Immunology Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a first-line therapy for rapidly killing
